Del Cioppo Sara, Faccioli Jessica, Ridola Lorenzo
Department of Medical and Surgical Sciences and Biotechnologies, Sapienza University of Rome, Rome 00185, Italy.
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome 00185, Italy.
World J Hepatol. 2025 Mar 27;17(3):104580. doi: 10.4254/wjh.v17.i3.104580.
Liver cirrhosis represents the final stage of liver diseases. The transition from the compensated to the decompensated form is a critical phase, as it is associated with a negative impact on patient prognosis. Therefore, having a tool to identify patients at higher risk of complications and mortality is an ideal goal. Currently, the validated scores for this purpose are the model for end-stage liver disease score and the Child-Pugh score. However, these scores have limitations, as they do not account for other factors associated with liver cirrhosis that are equally relevant from a prognostic perspective. Among these, alterations in body composition, particularly sarcopenia, increase the risk of mortality and should therefore be considered in the comprehensive assessment of patients with liver cirrhosis.
肝硬化是肝脏疾病的终末期。从代偿期到失代偿期的转变是一个关键阶段，因为它会对患者的预后产生负面影响。因此，拥有一种工具来识别并发症和死亡风险较高的患者是一个理想的目标。目前，用于此目的的经过验证的评分是终末期肝病模型评分和Child-Pugh评分。然而，这些评分存在局限性，因为它们没有考虑到与肝硬化相关的其他因素，而这些因素从预后角度来看同样重要。其中，身体成分的改变，特别是肌肉减少症，会增加死亡风险，因此在肝硬化患者的综合评估中应予以考虑。
